Redeye updates its estimates and valuation for Tradedoubler following the Q1 2025 report. While sales came in about 6% below our estimates, with 2% y/y growth due to a challenging market, Metapic's emergence helped drive margins, with gross profit up 11% compared to the same period in 2024. We expect market conditions to become progressively more favourable throughout the year, and, coupled with an active M&A ambition, its first US office, and low single-digit EBIT multiples, we see favorable conditions ahead. Our sales estimates are trimmed somewhat following the weaker-than-expected growth, resulting in a very slight downward revision to our fair value range.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/